UBS Group’s iShares Neuroscience and Healthcare ETF IBRN Stock Holding History

UBS Group’s Portfolio IBRN Stock Details IBRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.21K	Sell	67 -25	-27%	-$801	﹤0.01%	9334
2025 Q4	$2.97K	Buy	+92	New	+$2.77K	﹤0.01%	9166
2025 Q3	–	Sell	-85	Closed	-$1.86K	–	10575
2025 Q2	$1.86K	Buy	+85	New	+$1.85K	﹤0.01%	9557
2023 Q3	–	Sell	-1	Closed	-$24	–	9681
2023 Q2	$24	Buy	+1	New	+$25	﹤0.01%	8673

Other funds holding IBRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

Carson Wealth (CWM LLC) Omaha, Nebraska $38.1B AUM 19.66% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

UBS Group's IBRN Position: Q1 2026 in Review

UBS Group reduced its iShares Neuroscience and Healthcare ETF (IBRN) stake by 27% in Q1 2026, selling an estimated $801 and leaving 67 shares worth $2.21K. The position accounts for ﹤0.01% of the portfolio, ranked #9334.

UBS Group first reported a position in IBRN in Q2 2023 and has held it in 4 quarters since. The position peaked at $2.97K in Q4 2025. 5 funds tracked by Wall St. Rank hold IBRN as of Q1 2026.

UBS Group held 67 shares of iShares Neuroscience and Healthcare ETF worth $2.21K as of Q1 2026.
UBS Group sold 25 iShares Neuroscience and Healthcare ETF shares in Q1 2026, an estimated $801.
iShares Neuroscience and Healthcare ETF made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #9334 holding.
UBS Group first reported a position in iShares Neuroscience and Healthcare ETF in Q2 2023 and has held it in 4 quarters since.
UBS Group's iShares Neuroscience and Healthcare ETF position peaked at $2.97K in Q4 2025.
5 funds tracked by Wall St. Rank held iShares Neuroscience and Healthcare ETF as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.